In short
This article discusses the ongoing clinical trials of GB1211, a new drug being tested in combination with atezolizumab for the treatment of Non-Small Cell Lung Cancer (NSCLC). GB1211 is a galectin-3 inhibitor that shows promise in improving the effectiveness of immunotherapy for NSCLC patients. The trials aim to assess the safety, tolerability, and efficacy of this combination therapy in patients with advanced or metastatic NSCLC.
At a glance
- Drug Name
- GB1211 (5-Bromopyridin-3-yl 3-deoxy-1-thio-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-alfa-D-galactopyranoside)
- Drug Type
- Galectin-3 inhibitor
- Combination Therapy
- GB1211 + Atezolizumab
- Target Condition
- Non-Small Cell Lung Cancer (NSCLC) Stage IIIB or IV
- Trial Phase
- Phase I and Phase II (Integrated)
- Main Objectives
- Assess safety, tolerability, and efficacy of GB1211 with atezolizumab
- Key Eligibility Criteria
- Adults with NSCLC, measurable disease, PD-L1 expression ≥50%, no prior systemic chemotherapy or immune checkpoint inhibitors
- Primary Endpoints
- Adverse events, change in tumor size at Week 12
- Secondary Endpoints
- Overall response rate, duration of response, progression-free survival, pharmacokinetics
What is GB1211?
GB1211 is a new drug being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC). Its full scientific name is 5-bromopyridin-3-yl 3-deoxy-1-thio-3-[4-(3,4,5-trifluorophenyl)-1H-1,2,3-triazol-1-yl]-alfa-D-galactopyranoside. This medication comes in the form of a hard capsule that is taken by mouth.
How Does GB1211 Work?
GB1211 is classified as a galectin-3 inhibitor. Galectin-3 is a protein that plays a role in cancer growth and spread. By inhibiting or blocking this protein, GB1211 may help slow down or stop the progression of lung cancer.
In the current study, GB1211 is being tested in combination with another drug called atezolizumab. Atezolizumab is an immunotherapy drug that helps the body's immune system recognize and fight cancer cells.
Current Research on GB1211
A clinical trial is currently underway to investigate the safety and effectiveness of GB1211 in combination with atezolizumab for patients with Non-Small Cell Lung Cancer. This study is considered a Phase I and Phase II integrated trial, which means it will look at both the safety of the drug and how well it works.
The main goals of this study are:
- To assess the safety and tolerability of GB1211 when used with atezolizumab
- To determine the best dose of GB1211 to use with atezolizumab
- To evaluate how effective GB1211 is in treating NSCLC when combined with atezolizumab
Who Can Participate in the GB1211 Study?
The study is looking for patients with specific characteristics, including:
- Adults 18 years or older
- Diagnosed with NSCLC stage IIIB or IV
- Cancer that can be measured using specific criteria (RECIST v1.1)
- Cancer cells that express a certain level of a protein called PD-L1
- Have not received prior chemotherapy for advanced or metastatic disease
- Have not previously received immune checkpoint inhibitors
There are also several conditions that would prevent someone from participating in the study, such as certain heart conditions, autoimmune diseases, or other cancers.
Study Design
The study is divided into three parts:
- Part A: This part will determine the best dose of GB1211 to use with atezolizumab.
- Part B: This part will compare GB1211 plus atezolizumab to a placebo plus atezolizumab. Neither the patients nor the doctors will know who is receiving GB1211 or the placebo (this is called a double-blind study).
- Part C: This part will look at the long-term safety and effectiveness of GB1211 with atezolizumab.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to participating in this study:
Potential Benefits:
- Access to a new treatment that may be more effective than current options
- Close monitoring by healthcare professionals
- Contributing to the advancement of cancer research
Potential Risks:
- Unknown side effects from GB1211
- Possible interactions between GB1211 and atezolizumab
- The treatment may not be effective for everyone
It's important to note that this is an ongoing study, and the full benefits and risks of GB1211 are not yet known. Patients considering participating in this or any clinical trial should discuss the potential risks and benefits with their healthcare provider.